Autopsy report · NCT04416048

Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19

“Due to lower COVID-19 cases and therefore difficulties with the recruitment.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 8 months before it stopped.
• 111 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Charite University, Berlin, Germany

Sponsor type

University, hospital or other

Conditions

COVID-19

Interventions

Rivaroxaban; Standard Of Care (SOC)

Participants

111

Sites

24

Countries

Germany

Trials that died the same way

• ANTERO-5: Gastric Motility in Postoperative Ileus
  “Inadequate recruitment due to COVID-19 restrictions.” (90% match in meaning)
• Acute Effects of the Prostaglandin (Alprostadil) on Cerebral and Pulmonary Flow
  “Covid 19 and difficulty with recruitment” (85% match in meaning)
• Compression Wraps as Adjuvant Therapy in Management of Acute Systolic Heart Failure
  “challenges in recruitment due to covid-19” (85% match in meaning)
• A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients
  “Difficulty with patient recruitment due to COVID-19” (85% match in meaning)
• Lidocaine Administration During Flexible Bronchoscopy and Endobronchial Ultrasound
  “COVID lack of cases/recruitment” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.